hotspot -WSS

hotspot

author：hotspot 2025-10-06 10:32:44 - browse：57

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： A new nitrogen execution bill also undermines medical licensing

WSS

CRISPR technology availability, affordability needs to be expanded

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

In utero gene editing: an explainer

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

He's a Nobel laureate. Critics say he was misleading on Covid

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

hotspot

hotspot

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Illumina, CRISPR, Regeneron

State Dept. review finds Biden bears some blame for Afghanistan failures

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Duchenne breakthrough therapy leaves behind pioneering families

Medicare inequities exacerbate Puerto Rico’s health disparities

The cancer drug shortage isn’t new — and neither are the solutions

Steward Health Care expansion into Malta flopped

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Yancopoulos of Regeneron works to expand Dupixent success

knowledge

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Antivenom research: Lessons from HIV applied in search for universal antidote

In utero gene editing: an explainer

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Community Health Systems hospitals under DOJ investigation

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

knowledge

entertainment

Wikipedia

focus